Your browser doesn't support javascript.
loading
NAFLD and NASH are obesity-independent risk factors in COVID-19: Matched real-world results from the large PINC AI™ Healthcare Database.
Brozat, Jonathan F; Ntanios, Fady; Malhotra, Deepa; Dagenais, Simon; Katchiuri, Nino; Emir, Birol; Tacke, Frank.
Afiliación
  • Brozat JF; Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.
  • Ntanios F; Pfizer Inc, New York, New York, USA.
  • Malhotra D; Pfizer Inc, New York, New York, USA.
  • Dagenais S; Pfizer Inc, New York, New York, USA.
  • Katchiuri N; Pfizer Inc, New York, New York, USA.
  • Emir B; Pfizer Inc, New York, New York, USA.
  • Tacke F; Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.
Liver Int ; 44(3): 715-722, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38110709
ABSTRACT
BACKGROUND &

AIMS:

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are potential risk factors for severe pneumonia and other infections. Available data on the role of NAFLD/NASH in worsening outcomes for COVID-19 are controversial and might be confounded by comorbidities.

METHODS:

We used the PINC AI™ Healthcare Data Special Release (PHD-SR) to identify patients with COVID-19 (ICD-10) at approximately 900 hospitals in the United States. We performed exact matching (age, gender, and ethnicity) for patients with or without NAFLD/NASH, adjusting for demographics (admission type, region) and comorbidities (e.g., obesity, diabetes) through inverse probability of treatment weighting and then analysed hospitalisation-related outcomes.

RESULTS:

Among 513 623 patients with SARS-CoV-2 (COVID-19), we identified 14 667 with NAFLD/NASH who could be matched to 14 667 controls. Mean age was 57.6 (±14.9) years, 50.8% were females and 43.7% were non-Hispanic whites. After matching, baseline characteristics (e.g., age, ethnicity, and gender) and comorbidities (e.g., hypertension, obesity, diabetes, and cardiovascular disease) were well balanced (standard difference (SD) <.10), except for cirrhosis and malignancies. Patients with COVID-19 and NAFLD/NASH had higher FIB-4 scores, a significantly longer hospital length of stay (LOS) and intensive care LOS than controls (9.4 vs. 8.3 days, and 10.4 vs. 9.3, respectively), even after adjusting for cirrhosis and malignancies. Patients with COVID-19 and NAFLD/NASH also had significantly higher risk of needing invasive mandatory ventilation (IMV) (odds ratio 1.0727; 95% CI 1.0095-1.1400). Other outcomes were similar in both groups.

CONCLUSIONS:

In this large real-world cohort of patients hospitalised for COVID-19 in the United States, NAFLD/NASH were obesity-independent risk factors for complicated disease courses.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / Enfermedad del Hígado Graso no Alcohólico / COVID-19 / Neoplasias Límite: Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Liver Int Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / Enfermedad del Hígado Graso no Alcohólico / COVID-19 / Neoplasias Límite: Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Liver Int Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos